PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Nat Rev Neurosci. Author manuscript; available in PMC 2012 June 1.
Published in final edited form as:
PMCID: PMC3365568
NIHMSID: NIHMS376717

Corticotropin-releasing factor: innocent until proven guilty

The recent Review article by Heilig et al. (Pharmacogenetic approaches to the treatment of alcohol addiction. Nature Rev. Neurosci. 12, 670–684 (2011))1 expertly discussed strategies towards the development of therapeutics for alcoholism. However, we noticed a serious omission in their discussion of the corticotropin-releasing factor (CRF) system.

The authors described evidence supporting a role for CRF receptor 1 (CRF1) in alcohol-related behavioural traits, concluding that phenotypic screening may improve the clinical efficacy of CRF1 antagonists. However, they did not acknowledge that in addition to CRF and CRF1, this system includes three CRF-related ligands (the urocortins (UCNs): UCN1, UCN2 and UCN3), an additional receptor (CRF2) and the CRF binding protein (CRFBP)2. UCN2 and UCN3 bind CRF2 selectively, whereas UCN1 binds both CRF receptors and the CRFBP with greater affinities than does CRF itself2 (FIG. 1).

Figure 1
Relationships among corticotropin-releasing factor (CRF), urocortins and their targets

Although such information might be considered extraneous, we would like to correct a mistake in the authors’ Review1 that highlights precisely why it is necessary to acknowledge all CRF system components. Heilig et al. claimed that “blockade of stress-induced relapse is in part mediated by CRF1 blockade in the median raphe nucleus (MRN)”, citing a 2002 study3. In fact, those experiments used the non-selective4 antagonist D-Phe CRF12–41, leaving in question whether this effect was mediated by CRF1 or CRF2. On the surface, the error appears to be minor. However, because the authors neglected to mention all CRF system components, they not only falsely implicated CRF1, but also implied that the underlying ligand must be CRF.

This example illustrates a broader problem in the literature. Our analysis of the most recent 120 items retrieved by a PubMed search for CRF (or CRH) system involvement in alcoholism or addiction (excluding articles that focused solely on the hypothalamic–pituitary–adrenal axis) found that only 34.7% of these articles acknowledged UCN peptides. Furthermore, 53.3% of these articles implied a role for CRF without providing evidence against a role for UCNs.

We also identified several cases in which authors applied a ligand exogenously and inferred that the same ligand must mediate the effect endogenously. For example, the 2002 study discussed above found that intra-MRN CRF infusions reinstated alcohol-seeking, and the authors inferred that this mechanism mediated alcohol-seeking endogenously3. We should point out that many brain areas receive co-innervation by multiple ligands of the CRF system2,5,6, complicating this interpretation.

Heilig et al. probably excluded CRF2 and urocortins because orally available CRF2-specific drugs do not exist. However, we might argue that the slower development of CRF2-targeted therapies is a by-product of the issues outlined above. In fact, CRF2-selective agonists are potent inhibitors of alcohol intake7,8, and their therapeutic potential has been discussed9. Aside from the authors’ exclusion of CRF2, we remind them that UCN1 also exhibits high affinity for CRF1. Furthermore, genetic deletion of UCN1 dampened alcohol preference and alcohol-induced reward10, justifying the inclusion of UCNs in future conversation.

It is not our intent to diminish the role of CRF in alcohol-related behavioural traits. Rather, we hope that investigators will give careful thought to the endogenous mechanisms by which the CRF system influences behaviour and consider all suspects in order to generate a nuanced dissection of CRF system involvement in stress- and addiction-related disorders.

Acknowledgments

Authors are supported by US National Institutes of Health grants F31 AA021023 (W.J.G.) and AA013738, AA016647, AA010760 (A.E.R.).

Footnotes

Competing interests statement

The authors declare no competing financial interests.

FURTHER INFORMATION

Andrey Ryabinin’s homepage: http://tinyURL.com/RyabininLab

ALL LINKS ARE ACTIVE IN THE ONLINE PDF

References

1. Heilig M, Goldman D, Berrettini W, O’Brien CP. Pharmacogenetic approaches to the treatment of alcohol addiction. Nature Rev Neurosci. 2011;12:670–684. [PMC free article] [PubMed]
2. Reul JM, Holsboer F. Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr Opin Pharmacol. 2002;2:23–33. [PubMed]
3. Le AD, Harding S, Juzytsch W, Fletcher PJ, Shaham Y. The role of corticotropin-releasing factor in the median raphe nucleus in relapse to alcohol. J Neurosci. 2002;22:7844–7849. [PubMed]
4. Perrin MH, Sutton SW, Cervini LA, Rivier JE, Vale WW. Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of corticotropin-releasing factor receptors. J Pharmacol Exp Ther. 1999;288:729–734. [PubMed]
5. Bittencourt JC, et al. Urocortin expression in rat brain: evidence against a pervasive relationship of urocortin-containing projections with targets bearing type 2CRF receptors. J Comp Neurol. 1999;415:285–312. [PubMed]
6. Deussing JM, et al. Urocortin 3 modulates social discrimination abilities via corticotropin-releasing hormone receptor type 2. J Neurosci. 2010;30:9103–9116. [PubMed]
7. Sharpe AL, Phillips TJ. Central urocortin 3 administration decreases limited-access ethanol intake in nondependent mice. Behav Pharmacol. 2009;20:346–351. [PMC free article] [PubMed]
8. Funk CK, Koob GF. A CRF2 agonist administered into the central nucleus of the amygdala decreases ethanol self-administration in ethanol-dependent rats. Brain Res. 2007;1155:172–178. [PMC free article] [PubMed]
9. Lowery EG, Thiele TE. Pre-clinical evidence that corticotropin-releasing factor (CRF) receptor antagonists are promising targets for pharmacological treatment of alcoholism. CNS Neurol Disord Drug Targets. 2010;9:77–86. [PMC free article] [PubMed]
10. Giardino WJ, Cocking DL, Kaur S, Cunningham CL, Ryabinin AE. Urocortin-1 within the centrally-projecting Edinger-Westphal nucleus is critical for ethanol preference. PLoS ONE. 2011;6:e26997. [PMC free article] [PubMed]